Inhibition of STAT3 sensitizes pancreatic cancer cells to tumor growth inhibition and apoptosis induced by Src or EGFR inhibitors, suggesting that co-inhibition of STAT3 may increase the efficacy of targeted therapeutics [46], [47]. Here, SRC is linked to familial pancreatic carcinoma.